ClinicalTrials.gg
CompletedNCT04124419Updated Feb 27, 2026Results posted

Safety and Efficacy of Combined EMS and RF Treatments

An interventional study of Treatment with Evolve System in Non-invasive Circumference Reduction, sponsored by InMode MD Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by InMode MD Ltd. (part of InMode Ltd.) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this trial is to evaluate the safety and efficacy of the Evolve device utilizing the Ti10 and Tone applicators for abdominal non-invasive circumference reduction and skin tightening

02

Conditions studied

  • Non-invasive Circumference Reduction
03

In context

Lead sponsor

InMode MD Ltd. is the lead sponsor of 25 studies on the registry; 4 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 8 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Signed to participate in the study.
  • Female and male subjects,18 - 65 years of age at the time of enrolment
  • ≤ 30
  • If female, not pregnant, lactating and must be either , surgically sterilized, or using a medically acceptable form of at least 3 months prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
  • In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with (e.g. not menopause).
  • General good health confirmed by medical history and skin examination of the treated area.
  • Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.
  • The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods for the last 6 months and during the entire study period.

Exclusion criteria

Exclusion Criteria:

  • - Pacemaker or internal defibrillator, or any other metallic or electronic implant anywhere in the body.
  • Permanent implant in the treated area such as metal plates, screws and metal piercing, silicone implants or an injected chemical substance, unless deep enough in the periosteal plane.
  • Intra-dermal or superficial sub-dermal areas that have been injected with HA/collagen/fat injections or other augmentation methods with bio-material during last 6 months.
  • Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles.
  • Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
  • Pregnancy and nursing.
  • Impaired immune system due to diseases such as AIDS and , disorders or use of immunosuppressive medications.
  • Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  • Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
  • History of bleeding coagulopathies, or use of anticoagulants in the last 10 days.
  • Any surgical procedure in the treatment area within the last 6 months or before complete healing.
  • Having received treatment with light, laser, RF, or other devices in the treated area within 3 months, or before complete healing.
  • Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
  • As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.

    Device: Treatment with Evolve System

Interventions

  • DeviceTreatment with Evolve System

    EMS and RF Treatment

06

What researchers measure

Primary outcomes

  1. Change in Circumference Reduction

    Change in circumference measured in centimeters from baseline to 6 months following the last treatment session. Circumference was measured using a standard measuring tape. Negative values indicate a reduction in circumference.

    Time frame: Baseline to 6 months following last treatment session

Secondary outcomes

  1. Change in Abdomen Area Appearance Assessed by Investigator

    \- Investigator assessment of the skin appearance comparing pre and post treatment using 0 - 4 -points Likert scale at follow up visits: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference Higher score = better improvement

    Time frame: 6 month

  2. Subject Improvement Assessment

    Improvement assessment will be performed independently by the subject himself using 4 points Likert scale questionnaire (Global Aesthetic Improvement Scale), as follows: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference.

    Time frame: 6 Months

  3. Subject Satisfaction Assessment

    Subject assessment of satisfaction will be filled out by subjects using a 5-points Likert scale, as follows: +2 = Very satisfied; +1 = Satisfied; 0 = Indifferent; -1 = Disappointed; -2 = Very disappointed. Higher scores indicate greater satisfaction.

    Time frame: 6 months

07

Results

Posted Feb 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment Arm
Started20
Completed17
Not completed3
Withdrew: Lost to follow-up3

Outcome measures

PrimaryChange in Circumference Reduction

Change in circumference measured in centimeters from baseline to 6 months following the last treatment session. Circumference was measured using a standard measuring tape. Negative values indicate a reduction in circumference.

Time frame:
Baseline to 6 months following last treatment session
Reported as:
Median · centimeters (cm)
Change in Circumference Reduction
centimeters (cm)Treatment Arm
Change in Circumference Reduction-0.86 (-1.46 to 1.5)
SecondaryChange in Abdomen Area Appearance Assessed by Investigator

\- Investigator assessment of the skin appearance comparing pre and post treatment using 0 - 4 -points Likert scale at follow up visits: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference Higher score = better improvement

Time frame:
6 month
Reported as:
Mean · score (0-4 Likert scale)
Change in Abdomen Area Appearance Assessed by Investigator
score (0-4 Likert scale)Treatment Arm
Change in Abdomen Area Appearance Assessed by Investigator1.36 ± 0.64
SecondarySubject Improvement Assessment

Improvement assessment will be performed independently by the subject himself using 4 points Likert scale questionnaire (Global Aesthetic Improvement Scale), as follows: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference.

Time frame:
6 Months
Reported as:
Mean · score (0-4 Likert scale)
Subject Improvement Assessment
score (0-4 Likert scale)Treatment Arm
Subject Improvement Assessment1.9 ± 1.23
SecondarySubject Satisfaction Assessment

Subject assessment of satisfaction will be filled out by subjects using a 5-points Likert scale, as follows: +2 = Very satisfied; +1 = Satisfied; 0 = Indifferent; -1 = Disappointed; -2 = Very disappointed. Higher scores indicate greater satisfaction.

Time frame:
6 months
Reported as:
Mean · score on a scale
Subject Satisfaction Assessment
score on a scaleTreatment Arm
Subject Satisfaction Assessment1.18 ± 0.385

Adverse events

Collected over From first treatment session through 6 months after the last treatment session.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm0/17 (0%)0/17 (0%)0/17 (0%)

Baseline characteristics

Age, Customized
Age, Customized(years)Treatment
Age38.158 ± 9.63
Sex: Female, Male
Sex: Female, Male(Participants)Treatment
Female16
Male1
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Treatment
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)Treatment
Type I1
Type II5
Type III4
Type IV5
Type V2
Type VI0
08

Study locations

2 sites
  • Avance Plastic Surgery Institute
    Reno, Nevada 89511, United States
  • BodySculpt
    New York, New York 10019, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in May 2021, 22 months.

Results were first posted in Feb 2026, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2019
First posted
Oct 11, 2019
StartActual
Jul 19, 2019
Primary completionActual
May 19, 2021
CompletionActual
May 19, 2021
Results first posted
Feb 27, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04124419
Lead sponsor
InMode MD Ltd.
Responsible party
Sponsor
First posted
Oct 11, 2019
Start date
Jul 19, 2019
Primary completion
May 19, 2021
Completion
May 19, 2021
Results posted
Feb 27, 2026
Last update
Feb 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion